Wahlström G
Psychopharmacology (Berl). 1978 Oct 31;59(2):123-8. doi: 10.1007/BF00427745.
Male rats were forced to drink a barbital solution as their only drinking fluid for 33 weeks. During the last part of the treatment the average dose of barbital was around 200 mg/kg/day. In the abstinence period after barbital treatment, tolerance was recorded with a hexobarbital anaesthesia threshold utilizing an EEG criterium. Convulsions were recorded in jiggle cages. On days 3 and 28 of the abstinence period, i.p. pretreatment with atropine (2, 4, and 8 mg/kg) was given 1.5 h before threshold determinations. The barbital treatment induced a clear tolerance to the hexobarbital, which still could be detected on day 28 of abstinence. Atropine (8 mg/kg) reduced the hexobarbital threshold in tolerant and in control animals at both the time of maximum tolerance (day 3) and later during abstinence (day 28). The magnitude of the response was greater in tolerant animals, but no parallel shift in the dose-response curve was seen. The convulsions during abstinence were reduced for at least 8 h after atropine treatment (8mg/kg) on day 3. These results support the hypothesis that cholinergic mechanisms are involved in the changes induced by chronic barbiturate treatments.
雄性大鼠被强制饮用巴比妥溶液作为其唯一的饮用水，持续33周。在治疗的最后阶段，巴比妥的平均剂量约为200毫克/千克/天。在巴比妥治疗后的戒断期，利用脑电图标准通过己巴比妥麻醉阈值记录耐受性。在抖动笼中记录惊厥情况。在戒断期的第3天和第28天，在阈值测定前1.5小时腹腔注射给予阿托品（2、4和8毫克/千克）进行预处理。巴比妥治疗诱导了对己巴比妥的明显耐受性，在戒断的第28天仍可检测到。在最大耐受期（第3天）和戒断后期（第28天），阿托品（8毫克/千克）均降低了耐受动物和对照动物的己巴比妥阈值。耐受动物的反应幅度更大，但未观察到剂量反应曲线的平行移动。在第3天，阿托品治疗（8毫克/千克）后，戒断期间的惊厥至少减少了8小时。这些结果支持了胆碱能机制参与慢性巴比妥类药物治疗引起的变化这一假说。
